You didn't miss anything this weekend. Really, nothing happened, we looked. Oh, but the Eagles destroyed the St. Louis Rams 38-3 and the Phils took the weekend set against the Mets at Shea two games to one. But to dig up anything interesting in the biopharma universe, we had to wait til this morning. So here you go ... while you were driving to work:
- BMS and AstraZeneca released positive data from a study of their DPP-4 inhibitor saxagliptin (Onglyza) at the European Association for the Study of Diabetes meeting in Rome this morning. The companies said that the drug, which was submitted to FDA over the summer, "produced significant reductions across all key measures of glucose control studied."
- Also at EADS, Novo Nordisk said that its liraglutide human GLP-1 analog plus metformin and rosiglitazone led to improved blood glucose lowering, weight loss, blood pressure reduction and improvement in beta cell functioning. For more news out of this diabetes meeting, click here.
- Velcade was approved in the EU for combination with melphalan and prednisone for the treatment of patients with previously untreated multiple myeloma (MM) who are not eligible for high-dose chemotherapy with bone marrow transplant.
- Finally, a mini Press Release of (Last) Week: for the PR rep who is sending us pitches to cover the release of "Don't Mess With the Zohan" on DVD, this is for you.